ReviewNature reviews. Urology2012
Advanced prostate cancer--a case for adjuvant differentiation therapy.
Review in Nature reviews. Urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Suppression of dopamine receptor 2 inhibits the formation of human prostate cancer PC‑3‑derived cancer stem cell‑like cells through AMPK inhibition.Oncology letters · 2025Article
- Epigenetic disruption of the RARγ complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancer.bioRxiv : the preprint server for biology · 2024Article
- Acquisition Parameters Influence Diffusion Metrics Effectiveness in Probing Prostate Tumor and Age-Related Microstructure.Journal of personalized medicine · 2023Article
- The Emerging Role of the SLCO1B3 Protein in Cancer Resistance.Protein and peptide letters · 2020Review
- Epigenetic Control of Gene Expression in the Normal and Malignant Human Prostate: A Rapid Response Which Promotes Therapeutic Resistance.International journal of molecular sciences · 2019Review
- Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth.Cancer letters · 2017Article
- The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling.Oncogenesis · 2017Article
- The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.Molecular cancer research : MCR · 2017Article
- Loss of SLCO1B3 drives taxane resistance in prostate cancer.British journal of cancer · 2016Article
- Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer.International journal of molecular sciences · 2016Review
- Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.BMC cancer · 2016Article
- CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.Oncotarget · 2015Article
- TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.Oncotarget · 2015Article
- Multi-Drug Resistance ABC Transporter Inhibition Enhances Murine Ventral Prostate Stem/Progenitor Cell Differentiation.Stem cells and development · 2015Article
- Molecular pathways and targets in prostate cancer.Oncotarget · 2014Review
- DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation.Cell death and differentiation · 2014Article
- Conserved two-step regulatory mechanism of human epithelial differentiation.Stem cell reports · 2014Article
- Distinct phenotypes of human prostate cancer cells associate with different adaptation to hypoxia and pro-inflammatory gene expression.PloS one · 2014Article
- IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9.Endocrine-related cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of novel therapies such as abiraterone acetate and sipuleucel-T has improved the outlook for patients with advanced-stage and castration-resistant prostate cancer. However, the beneficial effects of these drugs are only measured in months. Moreover, the National Institute for Health and Clinical Excellence in the UK had ruled that the use of abiraterone acetate was not cost-effective before cost revision by the manufacturers. The FDA statement asserting that the use of 5α-reductase inhibitors for prostate cancer chemoprevention could increase the risk of developing high-grade prostate cancer also indirectly questions the value of direct androgen response manipulation for long-term benefit. These reports illustrate the need for a fresh and comprehensive analysis of advanced prostate cancer pathology to promote the next generation of effective adjuvant therapies. One such avenue is that of differentiation therapy, which seeks to promote the differentiation of cancer stem cells into a phenotype more sensitive to anticancer therapy than their parents. Using differentiation therapy with current antiandrogen therapies should augment our armoury of treatment for the management of advanced prostate cancer.
Indexed as
Identifiers
22890299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.